USPTO 2015–2025 USPTO PatentsView US Corporation

Direct Flow Medical, Inc.

USPTO PatentsView assignee record - 5 granted patents across 10 technology areas, active 2016–2017. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

21.6

Avg claims per patent

-100%

5-year filing velocity

The verdict

Direct holds 5 US patents across 10 technology areas, rank #46,286 of 50,000 tracked assignees.

#46,286
of 50,000 US assignees by volume: Top 66%
by Innovation Score (30.3/100): 21.6
avg claims per patent: -100%
filing velocity, last 5 yrs

Portfolio overview

Direct Flow Medical, Inc. has been granted 5 US utility patents between 2016 and 2017, placing Direct Flow Medical, Inc. at rank #46,286 across all assignees tracked by PlainPatent. This portfolio spans 10 distinct Cooperative Patent Classification (CPC) subclasses, averaging 21.6 claims per patent with primary concentration in A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE). As a US Corporation, Direct Flow Medical, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Direct sits between Digital Medical Technologies, Llc (5 patents, rank #46,282) and Displax S.a. (5 patents, rank #46,290) - the closest US assignees by grant volume. The composite Innovation Score of 30.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 0 grants, compared with 5 in the 2015–2019 window, a -100% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Direct Flow Medical, Inc.'s 21.6 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 10 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Direct Flow Medical, Inc. against peers pursuing similar technology classes.

Digital Medical

5
Digital Rise Tech…

5
Digitalocean

5
Dimension

5
Discgenics

5
Discount Ramps com

5
Dishcare

5
Displax

5
Direct Flow Medic… ◀

5

What this shows Direct holds 5 patents at rank #46,286, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Direct

By rank, the assignees closest to #46,286 in granted patent volume.

Leaders in A61F (Filters Implantable INTO Blood Vessels)

Other assignees with the most granted patents in Direct's primary technology class.

Direct's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

30 Top 66% higher than 34% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2017

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Direct Flow Medical, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	4	80.0%
2017	1	20.0%

Which technologies does Direct Flow Medical, Inc. patent most?

A61F - FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRS 5

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 2

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 2

B29L - INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES 1

A61L - METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES 1

B29C - SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING 1

C08G - MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS 1

C08L - COMPOSITIONS OF MACROMOLECULAR COMPOUNDS 1

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 1

Y10S - TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS 1

Top 10 of 10 technology areas

Patent Moat Analysis

Portfolio Volume Light

Tech Breadth Focused

Claim Depth Complex

Velocity Declining

Where it ranks

Overall rank by patents

#46,286

Across all tracked assignees

Innovation Score

30.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Direct Flow Medical, Inc. hold?

Direct Flow Medical, Inc. holds 5 US granted patents filed between 2016 and 2017, spanning 10 technology areas.

What is Direct Flow Medical, Inc.'s Innovation Score?

Direct Flow Medical, Inc. has an Innovation Score of 30.3 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Direct Flow Medical, Inc. focus on?

Direct Flow Medical, Inc.'s top technology area is A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRS) with 5 patents. The company has filed patents in 10 CPC subclasses total.

Is Direct Flow Medical, Inc.'s patent filing rate increasing or decreasing?

Direct Flow Medical, Inc.'s recent filing velocity is -100% compared to the prior five-year period. Filing activity has slowed relative to earlier years.

What does claim depth mean for Direct Flow Medical, Inc.'s patents?

Direct Flow Medical, Inc.'s patents average 21.6 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.

How is the Direct Flow Medical, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Direct's 5 grants land it in the top 66% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Direct ranks #46,286 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61F - see who else leads that technology area. A61F leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.